Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) (NCT05173987)
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been treated with prior systemic chemotherapy. The primary study hypotheses are that pembrolizumab is superior to the combination of carboplatin and paclitaxel with respect to Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and Overall Survival (OS).
Who can join: Review the eligibility criteria below.
Location: HonorHealth-USOR HonorHealth ( Site 8000) — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (194 Sites)
Showing the first 25 of 194 sites.
- HonorHealth-USOR HonorHealth ( Site 8000) — Phoenix, Arizona
- Moores Cancer Center ( Site 0037) — La Jolla, California
- Kaiser Permanente Riverside Medical Center ( Site 0045) — Riverside, California
- Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0013) — New Haven, Connecticut
- Mount Sinai Cancer Center ( Site 0018) — Miami Beach, Florida
- Sarasota Memorial Heath Care System ( Site 0005) — Sarasota, Florida
- Northside Hospital ( Site 0017) — Atlanta, Georgia
- Southeastern Regional Medical Center ( Site 0046) — Newnan, Georgia
- Midwestern Regional Medical Center,Inc. DBA CTCA, Chicago ( Site 0003) — Zion, Illinois
- St. Vincent Hospital and Health Care Center, Inc ( Site 0006) — Indianapolis, Indiana
- Baptist Health Lexington ( Site 0042) — Lexington, Kentucky
- Maryland Oncology Hematology, P.A.-USOR Maryland Oncology Hematology, P.A. ( Site 8002) — Rockville, Maryland
- University of Massachusetts Medical School-Division of Gynecologic Oncology ( Site 0008) — Worcester, Massachusetts
- Karmanos Cancer Institute ( Site 0029) — Detroit, Michigan
- St. Dominic's Hospital ( Site 0024) — Jackson, Mississippi
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0026) — Hackensack, New Jersey
- The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0023) — New York, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0016) — New York, New York
- Icahn School of Medicine at Mount Sinai ( Site 0052) — New York, New York
- Memorial Sloan Kettering Cancer Center ( Site 0009) — New York, New York
- FirstHealth Clinical Trials ( Site 0050) — Pinehurst, North Carolina
- Sanford Medical Center ( Site 0054) — Bismarck, North Dakota
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0055) — Fargo, North Dakota
- University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0039) — Cincinnati, Ohio
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0027) — Columbus, Ohio
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Endometrial Neoplasms
- Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer — Tucson, Arizona
- A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor — Little Rock, Arkansas
- Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) — Birmingham, Alabama
Explore by condition: All Endometrial Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.